3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
17
Neoplasm Metastasis
3
Endometrial Neoplasms
2
Anatomic Stage II Breast Cancer AJCC v8
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Liposarcoma
1
Leiomyosarcoma
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
HR+/HER2- Breast Cancer
1
HER2 Negative Breast Cancer
1
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
1
ER+ HER2- Advanced Breast Cancer
1
Breast Neoplasms, Male
1
Breast Diseases
1
Advanced Breast Cancer
1
Interventions
pembrolizumab
17
Bevacizumab
12
Standard of Care
10
Cyclophosphamide
9
Carboplatin
9
Doxorubicin
7
Cetuximab
7
Nivolumab
6
Exercise
6
olaparib
5
atezolizumab
5
Rituximab
5
Radiotherapy
5
Pemetrexed
5
Fluorouracil
5
Cisplatin
5
durvalumab
4
dostarlimab
4
abemaciclib
4
Temozolomide
4
Prednisone
4
Paclitaxel
4
Leucovorin
4
Blood Specimen Collection
4
venetoclax
3
temsirolimus
3
talazoparib
3
pertuzumab
3
obinutuzumab
3
ibrutinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
ribociclib
×
30 days
×
Clear all
NCT05768139
2026-05-22
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled